Next Article in Journal
Conflict of Interest: “Be Rigorous in Judging Ourselves and Gracious in Judging Others”
Previous Article in Journal
Medical Assistance in Dying for Cancer Patients One Year After Legalization: A Collaborative Approach at a Comprehensive Cancer Centre
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Meeting Report

Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer

1
Department of Surgery, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
2
Department of Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
3
Department of Oncology, BC Cancer, Vancouver, BC, Canada
4
Department of Surgery, Centre des maladies du sein, chu de Québec, Quebec City, QC, Canada
5
Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
6
Department of Oncology, CancerCare Manitoba, Winnipeg, MB, Canada
7
Department of Surgery, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada
8
Department Oncology, Cross Cancer Institute, Edmonton, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(5), 490-498; https://doi.org/10.3747/co.25.4153
Submission received: 10 July 2018 / Revised: 6 August 2018 / Accepted: 12 September 2018 / Published: 1 October 2018

Abstract

Therapy for breast cancer involves a complex interplay of three main treatment modalities: surgery, systemic therapy, and radiation therapy. The Canadian Consortium for Locally Advanced Breast Cancer (LABC) was established with the goal to convene a strong multidisciplinary team of breast oncology clinicians and scientists who are dedicated to the advancement of LABC research and treatment, with a vision to drive progress through increased collaboration across disciplines and throughout Canada. The most recent meeting in May 2017 highlighted the latest evidence and literature about the optimal use of neoadjuvant systemic therapy in breast cancer. There is a need for increased clinical and scientific collaboration and the development of guidelines for the use of emerging treatment strategies. The interactive meeting sessions fostered unique opportunities for academic debate and nurtured collaboration between the attendees.
Keywords: breast cancer; diagnosis; treatment; neoadjuvant therapy; locally advanced disease; surgery; radiation breast cancer; diagnosis; treatment; neoadjuvant therapy; locally advanced disease; surgery; radiation

Share and Cite

MDPI and ACS Style

Arnaout, A.; Lee, J.; Gelmon, K.; Poirier, B.; Lu, F.I.; Akra, M.; Boileau, J.F.; Tonkin, K.; Li, H.; Illman, C.; et al. Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer. Curr. Oncol. 2018, 25, 490-498. https://doi.org/10.3747/co.25.4153

AMA Style

Arnaout A, Lee J, Gelmon K, Poirier B, Lu FI, Akra M, Boileau JF, Tonkin K, Li H, Illman C, et al. Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer. Current Oncology. 2018; 25(5):490-498. https://doi.org/10.3747/co.25.4153

Chicago/Turabian Style

Arnaout, A., J. Lee, K. Gelmon, B. Poirier, F.I. Lu, M. Akra, J.F. Boileau, K. Tonkin, H. Li, C. Illman, and et al. 2018. "Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer" Current Oncology 25, no. 5: 490-498. https://doi.org/10.3747/co.25.4153

Article Metrics

Back to TopTop